Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: Evidence for a protective role for glucosamine in atherosclerosis

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Duan, Wenlan ^a   Paka, Latha ^b,c   Pillarisetti, Sivaram ^a  

^a Reddy US Therapeutics   (United States)

^b ANGION BIOMEDICA CORP   (United States)

^c North Shore Long Island Jewish Health System ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GLUCOSAMINE; GLUCOSE; GLYCOSAMINOGLYCAN; PERLECAN; HEPARIN; LOW DENSITY LIPOPROTEIN; PROTEOHEPARAN SULFATE; SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL CULTURE; CELL GROWTH; CELL ISOLATION; CELL LABELING; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IN VITRO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SMOOTH MUSCLE FIBER; SUBENDOTHELIUM; VASCULAR ENDOTHELIUM; ANIMAL; AORTA; C57BL MOUSE; CATTLE; CELL DIVISION; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECT; ENDOTHELIUM CELL; MALE; METABOLISM; MONOCYTE; MOUSE MUTANT; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CATTLE; CELL DIVISION; CELL MEMBRANE PERMEABILITY; ENDOTHELIAL CELLS; GLUCOSAMINE; GLUCOSE; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; MYOCYTES, SMOOTH MUSCLE; SULFATES;

EID: 27644474139     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-16     Document Type: Article

References (43)

1. Hsueh, WA, Law, R.E. Diabetes is a vascular disease. J. Investig. Med. 1998, 46:387-90.
2. Sowers; JR, Stump CS. Insights into the biology of diabetic vascular disease: whats new? Am J Hypertens. 2004, 17(11 Pt 2):2S-6S
3. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA,,Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide. production blocks three pathways of hyperglycaemic damage. Nature.. 2000, 404(6779):787-90
4. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005, 67(1):3-21
5. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic: vascular complications. Physiol Res. 2004, 53(2):131-42
6. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys. 2003, 1;419(1):80-8
7. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl. 2000, 77:S13-8
8. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991, 266(8):4706-12
9. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 1998,101(1):160-9
10. Goldberg HJ, Scholey J, Fantus IG. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerula mesangial cells. Diabetes. 2000, 49(5):863-71
11. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest. 1997, 99(9):2062-70
12. Iozzo, R.V, Cohen I.R, Grassel, S., and Murdoch A. D. The biology of perlecan: the multi faceted HSPG of basement membranes and pericellular matrices. Blochem. J. 1994, 302, 625-639
13. Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000, 10:60-5
14. Hollmann, J., Schmidt, A., von Bassewitz D.B.,and Buddecke, E. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteiosclerosis, 1989, 9,154-158
15. Volker, W., Schmidt, A., Oortmann, W., Broszey, T., Faber V., and Buddecke, E. Mapping of proteoglycans an atherosclerotic lesions. Eur. Heart J. 1990, 11, 29-40
16. Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest. 1992, 89(2):373-80
17. Stins, M. F., Maxfield, F.R., and Goldberg I.J.. Polarized binding of lipoprotein lipase to endothelial cells. Arterioscler. Thromb. 1992, 12:1437-1446
18. Edwards, I. J., Xu, H., Obunike, J. C., Goldberg, I. J., and Wagner, W. D. Differentiated macrophages synthesize a heparan sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase. Arteriosclero. Thromb. 1995, 15, 400-409
19. Pillarisetti, S., Obunike, J. C., and Goldberg, I. J. Lysolecithin induced alterations of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J. Biol. Chem. 1995, 270, 29760-29765
20. Paka, S., Goldberg, I. J., Obunike, J. C. Choi, S. Y., Saxena, U., Goldberg, I. D. and Pillarisetti, S. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle growth. J. Biol. Chem. 1999, 274, 36403-36408
21. Paka, L., Kako, Y., Obunike, J. C., and Pillarisetti, S. Apo E stimulates endothelial of heparan sulfate rich in biologically active heparin-like domains. J. Biol. Chem. 1999, 274, 4816-4823
22. Vogl-Willis CA, Edwards IJ. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol. 2004, 24(5):858-63
23. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem. 1991. 60:443-75
24. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest. 1997, 99(9):2173-82
25. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001, 27;357(9252):251-6
26. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab. 2001, 86(5):2099-103
27. Engelberg H. Endogenous heparin activity deficiency: the 'missing link' in atherogenesis? Atherosclerosis. 2001, 159(2):253-60
28. Ramasamy, S., Lipke, D.W., McClain, C.J., and Hennig, B. Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells. J. Cell. Physiol. 1995, 162, 119-126.
29. Nishinaga, M., Ozawa, T., and Shimada, K. Homocysteine, a thrombogenic, agent suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J. Clin. Invest. 1993, 92, 1381-1386
30. Pillarisetti, S., Paka, L., Obunike, J. C., Berglund, L., and Goldberg, I. J. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein (a), retention by subendothelial matrix. J. Clin. Invest. 1997, 100,867-874
31. Nader, H.B., Dietrich, C.P., Buonassisi, V., and Colburn, P. Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc. Natl. Acad. Sci. USA. 1987, 84:3565-3569
32. Ruoslahti, E., and Yamaguchi, Y. Proteoglycans as modulators of growth factor activities, Cell 1991, 64, 867-869
33. Castellot, J. J., Addonizio, M.L., Rosenberg, R., and Karnovsky, M..J. Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 1981, 90, 372-379
34. Weiser, M. C., Belknap, J. K., Grieshaber, S. S., Kinsella, M. G., and Majack, R. A. Developmental regulation of perlecan gene expression in aortic smooth muscle calls. Matrix Biol. 1996, 15, 331-340
35. Han, I., and Kudlow, J. E. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. 1997, Mol. Cell. Biol. 17, 2550-2556
36. McClain, D. A., Paterson, A. J., Roos, M.D., Wei, X., and Kudlow, J.E. Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle, cells. Proc. Natl. Acad. Sci. USA 1992, 89, 8150-8154
37. Sayeski, P. P., and Kudlow, J. E. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription. J. Biol. Chem. 1998, 271, 15237-15243
38. Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R., and Schieicher, E. D. High glucose induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 1998, 101, 160-169
39. Iozzo, R. V., Pillarisetti, J., Sharma, B., Murdoch, A. D., Danielson, K. G., Uitto, J., and Mauviel, A. Structural and functional characterization of human perlecan gene promoter. Transcriptional, activation of transforming growth factor-beta via a nuclear factor 1-binding element. J. Biol. Chem. 1997, 272, 5219-5228
40. Tesoriere, G., Dones, F., Magistro, D., and Castagnetta, L. Intestinal absorption of glucosamine and N-acetylglucosamine. Experentia 1972, 28, 770-771
41. Tannock LR, Little PJ, Wight TN, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res. 2002, 43(1):149-57
42. Stender, S., and Astrup, P. Glucosamine and experimental atherosclerosis: Increased wet weight and changed composition of cholesterol fatty acids in aorta of rabbits fed a cholesterol enriched diet with added glucosamine. Atherosclerosis 1977, 26, 205-213
43. McCarty, M. F. Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. Med. Hypotheses. 1997, 48, 245-251